Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics is well-positioned for success with its well-capitalized balance sheet, key development milestones met for ELVN-001, promising results from the ENABLE phase 1b trial, and FDA Fast Track Designation received. With a high likelihood of approval for ELVN-001 in second or later lines of treatment, this clinical-stage biopharmaceutical company is a strong investment opportunity.

Bears say

Enliven Therapeutics is facing several fundamental risks that may affect their financial performance and stock value in the future. These include potential competition from other pharmaceutical companies with similar products, challenges securing regulatory approvals for their main product candidate ELVN-001, potential market access and pricing issues, and potential equity dilution risks. The lack of current revenue and royalty fees also raises concerns about the company's ability to sustain itself in the short term.

ELVN has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 7 analysts, ELVN has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.